Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03454035 | Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors | recruiting | Phase 1 | 45 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07160335 | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | active not recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06425926 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 117 | Georgiamune IncINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | recruiting | Phase 1 | 21 | Kupando GmbHINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01989585 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | active not recruiting | Phase 1 / Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT06214156 | A Clinical Study of T3011 in Subjects With Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 42 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma(Uveal Melanoma) | not yet recruiting | Phase 1 / Phase 2 | 30 | ReBio PharmaINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05068102 | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab | active not recruiting | Phase 1 | 14 | Boehringer IngelheimINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07634380 | Sitagliptin With Pembro in RCC and Melanoma | recruiting | Phase 1 | 64 | Fernando Maciel BarbosaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06060613 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors(Agni-01) | recruiting | Phase 1 / Phase 2 | 208 | Obsidian Therapeutics, Inc.INDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04697576 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | recruiting | Phase 1 | 36 | Carlo ContrerasOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | enrolling by invitation | Phase 1 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05077137 | A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy(TdVax) | recruiting | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07086105 | A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma | recruiting | Phase 1 | 30 | Adze Biotechnology Australia Pty LtdINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04835805 | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | active not recruiting | Phase 1 | 65 | Genentech, Inc.INDUSTRY | 5 | Jul 1, 2026 | clinicaltrials |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | recruiting | Phase 1 | 15 | Inge Marie SvaneOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03311308 | A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | active not recruiting | Phase 1 | 23 | Yana NajjarOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06961357 | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | recruiting | Phase 1 / Phase 2 | 36 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06636435 | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | recruiting | Phase 1 | 66 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07027488 | AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors(Asher-BioAB821) | recruiting | Phase 1 | 50 | Yale UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | recruiting | Phase 1 / Phase 2 | 42 | Iovance Biotherapeutics, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials